PRQR vs SNY
ProQR Therapeutics N.v. and Sanofi, side by side — 5 fiscal years reported in EUR, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | PRQR | SNY |
|---|---|---|
| Revenue | €15.9M | €43.6B |
| Net income | €-42.2M | €7.8B |
| Gross margin | — | 77.2% |
| Net margin | −265.2% | 17.9% |
| Return on equity | −61.2% | 10.5% |
| Diluted EPS | −€0.40 | €6.37 |
| Dividend / share | — | €3.92 |
| Payout ratio | — | 61.1% |
| Free cash flow | €-53.8M | — |
| Equity | €49.4M | €71.4B |
| Net debt / equity | −1.77× | 0.15× |
| Current ratio | 3.09× | 1.09× |
| Revenue CAGR 5y | — | 3.9% |
| Profit CAGR 5y | — | −8.7% |
SNY bills 2742.7× the revenue of PRQR, and PRQR closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
5 years side by side
| Fiscal year | PRQR | SNY |
|---|---|---|
| FY2025 | €15.9M | €43.6B |
| FY2024 | €18.9M | €41.1B |
| FY2023 | €6.5M | €37.8B |
| FY2022 | €3.6M | €37.7B |
| FY2021 | €1.3M | €37.8B |
Net income by year
Bottom line
| Fiscal year | PRQR | SNY |
|---|---|---|
| FY2025 | €-42.2M | €7.8B |
| FY2024 | €-27.8M | €5.6B |
| FY2023 | €-28.1M | €5.4B |
| FY2022 | €-64.4M | €8.4B |
| FY2021 | €-60.7M | €6.2B |
Advertisement
AdSense · Rectangle 336×280